Cardiol To Advance CardiolRx To Phase III Trial Following Positive Results

Cardiol Therapeutics (TSX: CRDL) has seen success under a phase II trial conducted on CardiolRx, which is the company’s lead small molecule drug candidate. The drug is currently going through clinical trials for use in the treatment of heart disease, specifically recurrent pericarditis and acute myocarditis.

Read more